Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Volume 45, Issue 2, February 2020, Pages 79-148
 
MONOGRAPHS
 
  
 Sparsentan.
Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy.
Trachtman, H., Hogan, J.J., Tesar, V., Komers, R.
Drugs Fut 2020, 45(2): 79
Summary | Full Text: PDF 
 
  
  
 Trilaciclib hydrochloride.
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, Myelopreservation therapy, Treatment of small cell lung cancer, Treatment of triple-negative breast cancer.
Barquero, N.
Drugs Fut 2020, 45(2): 99
Summary | Full Text: PDF 
 
  
 
REVIEW ARTICLE
 
  
 Alzheimer's disease murine models: focus on late-onset disease.
Potenza, M.A., Nacci, C., Carratu, M.
Drugs Fut 2020, 45(2): 109
Summary | Full Text: PDF 
 
  
 
DRUGLINE
 
  
 Pipeline on the move.
Torramade, E., Molas, G., Presa, A.
Drugs Fut 2020, 45(2): 119
Full Text: PDF 
 
  
 
MEETING REPORTS
 
  
 American Heart Association – Scientific Sessions 2019. Philadelphia, Pennsylvania, USA – November 16-18, 2019.
Diaz, N.
Drugs Fut 2020, 45(2): 131
Summary | Full Text: PDF 
 
  
  
 American Society of Hematology – 61st Annual Meeting and Exposition. Orlando, Florida, USA – December 7-10, 2019.
Stringer, M., Walker, G., Sridevi, M.
Drugs Fut 2020, 45(2): 137
Summary | Full Text: PDF 
 
  
  
 Antibody Engineering & Therapeutics 2019. San Diego, California, USA – December 9-13, 2019.
Bofill, X.
Drugs Fut 2020, 45(2): 145
Summary | Full Text: PDF 
 
  
 
  



© 2020 Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy